| Nov 20 |
Down -35.74% in 4 Weeks, Here's Why PDS Biotechnology (PDSB) Looks Ripe for a Turnaround
|
| Nov 15 |
PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...
|
| Nov 14 |
PDS Biotechnology Corporation (PDSB) Q3 2024 Earnings Call Transcript
|
| Nov 14 |
PDS Biotechnology: Q3 Earnings Snapshot
|
| Nov 14 |
PDS Biotechnology GAAP EPS of -$0.29 misses by $0.01
|
| Nov 14 |
PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results
|
| Nov 14 |
Earnings Scheduled For November 14, 2024
|
| Nov 6 |
PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time
|
| Oct 22 |
PDS Biotechnology (PDSB) Upgraded to Strong Buy: Here's What You Should Know
|
| Oct 22 |
PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine
|
